Compare ATR & PCVX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ATR | PCVX |
|---|---|---|
| Founded | 1992 | 2013 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Plastic Products | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 9.3B | 8.7B |
| IPO Year | 1995 | 2020 |
| Metric | ATR | PCVX |
|---|---|---|
| Price | $130.00 | $62.08 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 4 | 5 |
| Target Price | ★ $170.25 | $88.25 |
| AVG Volume (30 Days) | 420.7K | ★ 1.2M |
| Earning Date | 04-30-2026 | 05-06-2026 |
| Dividend Yield | ★ 1.46% | N/A |
| EPS Growth | ★ 6.51 | N/A |
| EPS | ★ 5.89 | N/A |
| Revenue | ★ $3,777,181,000.00 | N/A |
| Revenue This Year | $5.29 | N/A |
| Revenue Next Year | $4.98 | N/A |
| P/E Ratio | $22.33 | ★ N/A |
| Revenue Growth | ★ 5.42 | N/A |
| 52 Week Low | $103.23 | $28.09 |
| 52 Week High | $164.28 | $65.00 |
| Indicator | ATR | PCVX |
|---|---|---|
| Relative Strength Index (RSI) | 52.83 | 63.13 |
| Support Level | $129.06 | $42.30 |
| Resistance Level | $133.25 | $65.00 |
| Average True Range (ATR) | 3.01 | 2.30 |
| MACD | 1.06 | 0.60 |
| Stochastic Oscillator | 77.24 | 85.71 |
Headquartered in Crystal Lake, Illinois, AptarGroup is a leading global supplier of dispensing systems such as aerosol valves, pumps, closures, and elastomer packaging components to the consumer goods and pharmaceutical markets. Its sales are primarily from Europe (49% of sales) and the United States (28%), with China contributing 5% and other countries contributing 17%. It operates three business segments, Pharma, Beauty, and Closures. Pharma generates over two thirds of group profits.
Vaxcyte Inc is a clinical-stage vaccine company engineering high-fidelity vaccines to protect humankind from the consequences of bacterial diseases. It uses the XpressCF cell-free protein synthesis platform to develop potentially superior and novel conjugate and protein vaccine candidates for adult and pediatric indications. The company's product pipeline includes: VAX-31, VAX-24, and VAX-XL PCV vaccine candidates; VAX-A1, a Novel Group A Strep Vaccine; and VAX-GI, a Novel Shigella Vaccine, among others, in their different stages of development.